Radionetics Oncology develops small molecule radiopharmaceuticals that target G protein-coupled receptors (GPCRs) to deliver therapeutic radioisotopes directly to solid tumors, enhancing treatment precision. This approach addresses the need for effective cancer therapies by enabling targeted radiation delivery while minimizing damage to surrounding healthy tissue.
Funding
$54.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DBFounders
Product
Problem
Many solid tumors lack effective treatment options due to the difficulty in delivering radiation directly to cancer cells without harming surrounding healthy tissue. Traditional radiation therapies often result in systemic toxicity and limited efficacy, particularly for tumors located deep within the body.
Solution
Radionetics Oncology is developing small molecule radiopharmaceuticals that selectively target G protein-coupled receptors (GPCRs) overexpressed on solid tumors. By linking a therapeutic radioisotope to a small molecule ligand, the company's approach enables targeted delivery of radiation directly to the tumor site. This precision medicine strategy aims to maximize cancer cell death while minimizing off-target effects and improving patient outcomes. Radionetics' modular platform allows for selection of the optimal radioisotope based on cancer biology to achieve the desired therapeutic effect.
Target Audience
The primary target audience includes cancer patients with solid tumors expressing specific GPCRs, as well as oncologists and medical professionals seeking more precise and effective radiation therapies.
Features
- Targets GPCRs, a largely unexplored class of receptors for radiopharmaceuticals, with >65 GPCRs exhibiting increased tumor expression.
- Utilizes a differentiated small molecule approach based on decades of drug development experience.
- Employs a modular and flexible platform, enabling radioisotope selection based on cancer biology for optimal therapeutic effect.
- Developing a pipeline of novel small molecule radioligands targeting GPCRs for the treatment of a broad range of cancers, including breast and lung cancer.
- Theranostic approach allows for both diagnostic imaging and targeted therapy using the same radiopharmaceutical.